retatrutide clinical trial weight loss results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Eli Lilly's Retatrutide Phase 3

Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk

doi: 10.1210/en.2012-1786 [DOI] [PubMed] [Google Scholar] 75.Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg E, Juhl CB

The study revealed that those taking these semaglutide-based drugs for weight loss were seven times more likely to experience the condition than those on other obesity treatments

Matrix metalloproteinase-9 delays wound healing in a murine wound model

Irwin M

Management strategies, such as dietary modifications (e.g., low-carbohydrate, high-protein diets), pharmacologic interventions (e.g., acarbose, somatostatin analogs, GLP-1 receptor antagonists, dasiglucagon), and surgical/endoscopic approaches, are reviewed for their efficacy across different patient populations